Market revenue in 2023 | USD 38.7 million |
Market revenue in 2030 | USD 49.1 million |
Growth rate | 3.4% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Home Care |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Home Care, Research & Manufacturing |
Key market players worldwide | Thermo Fisher Scientific Inc, Qiagen NV, Illumina Inc, Roche Holding AG ADR, BD, Agilent Technologies Inc, Myriad Genetics Inc, Koninklijke Philips NV, Abbott Laboratories, Hitachi Ltd, Danaher Corp, Prestige Medical |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer diagnostic market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 62.53% in 2023. Horizon Databook has segmented the Middle East & Africa pancreatic cancer diagnostic market based on hospitals, outpatient facilities, home care, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
MEA is expected to witness significant growth opportunities, as a majority of the market is untapped due to the unavailability of organized cancer screening programs in this region, especially in underdeveloped African economies. In the past few years, countries such as the UAE, Morocco, & South Africa have organized cancer screening programs.
Collaborations of various companies with government institutes to supply these tests are expected to boost the market. These initiatives are anticipated to lead to the development of newer cancer detection tests. Novel cancer tests, including liquid biopsy, are expensive. Hence, there is a shortage of experienced professionals to perform these tests.
However, in January 2024, Guardant Health, Inc., a leading precision oncology company, and Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, partnered to promote Guardant Health’s liquid & tissue biopsy tests for cancer screening, recurrence monitoring, and tumor mutation profiling for all solid cancers across the Middle East and North Africa (MENA).
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa pancreatic cancer diagnostic market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa pancreatic cancer diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account